Paper Details

  1. Home
  2. Paper Details

Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.

Author: HansenJ B, KonstantinouM P, PuigL, ReichK, WarrenR B

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A post hoc analysis of two phase 3 trials of brodalumab for moderate-to-severe psoriasis found that brodalumab was associated with higher levels of complete clearance (PASI 100) and greater cumulative benefit over time compared to ustekinumab, regardless of prior treatment experience.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The pathway for treatment of psoriasis is partly dependent upon disease severity, and patients may experience inadequate response at any point along the treatment pathway. Patients who repeatedly fail therapy represent a population in whom effective and well-tolerated treatment options a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jdv.17433

データ提供：米国国立医学図書館（NLM）

Brodalumab vs. Ustekinumab: A Head-to-Head Comparison for Psoriasis Treatment

The world of [psoriasis] treatment is constantly evolving. This research compares the effectiveness of two [biologic therapies], [brodalumab] and [ustekinumab], in achieving [complete clearance] of [psoriasis] symptoms in individuals with [moderate-to-severe psoriasis]. The study analyzed data from two phase 3 clinical trials, focusing on patients with varying prior treatment histories.

Brodalumab: A Promising Option for Challenging Cases

The results demonstrate that [brodalumab] consistently outperformed [ustekinumab] in achieving [complete clearance], as measured by the [PASI 100] score, across all treatment subgroups. This finding holds true regardless of whether patients were [treatment-naïve], had previously received [systemic therapy], or had failed prior [biologic therapy]. Furthermore, [brodalumab] was associated with lower rates of [inadequate response] and greater [cumulative treatment benefit] compared to [ustekinumab].

Dr.Camel's Conclusion

This study offers valuable insights for clinicians managing [psoriasis] patients. [Brodalumab] emerges as a compelling treatment option for individuals with [moderate-to-severe psoriasis], particularly those who have experienced [treatment failure] with other therapies. As always, the choice of treatment should be individualized based on patient characteristics and preferences, in consultation with a qualified healthcare professional.

Date :
  1. Date Completed 2021-09-20
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34076919

DOI: Digital Object Identifier

10.1111/jdv.17433

Related Literature

Article Analysis
・Effective treatment of psoriasis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.